Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock: Insider Christophe Jean Sells 10,000 Shares

Rhythm Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Christophe Jean sold 10,000 Rhythm Pharmaceuticals shares at an average of $109.66, worth about $1.10 million. The sale was made under a pre-arranged Rule 10b5-1 plan; he retained 11,712 shares.
  • Rhythm reported quarterly revenue of $92.13 million, up 79.6% year over year and above estimates, while its loss per share of $0.61 was narrower than analysts expected.
  • Analysts hold a consensus “Moderate Buy” rating with an average price target of $142. The shares traded at $119.04 in the article’s report.
  • MarketBeat previews the top five stocks to own by December 1st.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) Director Christophe Jean sold 10,000 shares of the firm's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $109.66, for a total transaction of $1,096,600.00. Following the transaction, the director owned 11,712 shares in the company, valued at $1,284,337.92. This represents a 46.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals Stock Performance

Shares of Rhythm Pharmaceuticals stock traded up $2.43 on Wednesday, reaching $119.04. The stock had a trading volume of 2,015,062 shares, compared to its average volume of 867,630. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $74.50 and a fifty-two week high of $122.20. The business's 50-day moving average price is $97.27 and its two-hundred day moving average price is $97.53. The stock has a market cap of $8.25 billion, a P/E ratio of -41.05 and a beta of 2.17.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.10. Rhythm Pharmaceuticals had a negative return on equity of 171.16% and a negative net margin of 69.03%. The company had revenue of $92.13 million during the quarter, compared to analyst estimates of $85.56 million. During the same period in the previous year, the company earned ($0.82) earnings per share. The company's quarterly revenue was up 79.6% compared to the same quarter last year. As a group, equities analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.90 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RYTM has been the subject of a number of recent analyst reports. Citizens Jmp increased their target price on shares of Rhythm Pharmaceuticals from $160.00 to $166.00 and gave the stock a "market outperform" rating in a research report on Wednesday, November 4th. Oppenheimer reissued a "market perform" rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, November 4th. Needham & Company LLC decreased their target price on Rhythm Pharmaceuticals from $130.00 to $114.00 and set a "buy" rating on the stock in a report on Tuesday, November 3rd. JPMorgan Chase & Co. lowered their target price on Rhythm Pharmaceuticals from $145.00 to $142.00 and set an "overweight" rating for the company in a research note on Friday, November 6th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, November 4th. Eighteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Rhythm Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $142.00.

Check Out Our Latest Stock Analysis on Rhythm Pharmaceuticals

Hedge Funds Weigh In On Rhythm Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RYTM. Algert Global LLC raised its position in shares of Rhythm Pharmaceuticals by 20.6% in the third quarter. Algert Global LLC now owns 100,628 shares of the company's stock valued at $9,581,000 after purchasing an additional 17,197 shares during the period. Castleark Management LLC purchased a new position in Rhythm Pharmaceuticals in the 3rd quarter valued at approximately $5,041,000. Virtu Financial LLC bought a new stake in Rhythm Pharmaceuticals during the 3rd quarter valued at $334,000. Bellevue Group AG raised its holdings in Rhythm Pharmaceuticals by 96.1% during the 3rd quarter. Bellevue Group AG now owns 1,992 shares of the company's stock valued at $190,000 after acquiring an additional 976 shares during the period. Finally, Cetera Investment Advisers lifted its position in shares of Rhythm Pharmaceuticals by 56.5% during the third quarter. Cetera Investment Advisers now owns 3,284 shares of the company's stock worth $313,000 after acquiring an additional 1,186 shares in the last quarter.

Rhythm Pharmaceuticals Company Profile

(Get Free Report)

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.

Further Reading

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?

Before you consider Rhythm Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.

While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines